Literature DB >> 11569905

Mycophenolate-mofetil in the treatment of refractory multiple sclerosis.

N Ahrens, A Salama, J Haas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11569905     DOI： 10.1007/s004150170122

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  10 in total

1.  A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.

Authors:  Elliot M Frohman; Gary Cutter; Gina Remington; Hongjiang Gao; Howard Rossman; Bianca Weinstock-Guttman; Jacqueline E Durfee; Amy Conger; Ellen Carl; Katherine Treadaway; Eric Lindzen; Amber Salter; Teresa C Frohman; Anjali Shah; Angela Bates; Jennifer L Cox; Michael G Dwyer; Olaf Stüve; Benjamin M Greenberg; Michael K Racke; Robert Zivadinov
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

2.  Mycophenolate mofetil for lupus related myelopathy.

Authors:  C C Mok; A Mak; C H To
Journal:  Ann Rheum Dis       Date:  2006-07       Impact factor: 19.103

Review 3.  Immunosuppressive agents in multiple sclerosis.

Authors:  Oliver Neuhaus; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 4.  [Cell depletion and myoablation for neuroimmunological diseases].

Authors:  M Diebold; L Kappos; T Derfuss
Journal:  Nervenarzt       Date:  2016-08       Impact factor: 1.214

Review 5.  Role of immunosuppressive therapy for the treatment of multiple sclerosis.

Authors:  James M Stankiewicz; Hadar Kolb; Arnon Karni; Howard L Weiner
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 6.  [Multiple sclerosis: potential therapeutic options and update of ongoing studies].

Authors:  H Wiendl; H C Lehmann; R Hohlfeld; H-P Hartung; B C Kieseier
Journal:  Nervenarzt       Date:  2004-06       Impact factor: 1.214

Review 7.  [Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis].

Authors:  C Kleinschnitz; S G Meuth; B C Kieseier; H Wiendl
Journal:  Nervenarzt       Date:  2007-08       Impact factor: 1.214

Review 8.  Oral disease-modifying treatments for multiple sclerosis: the story so far.

Authors:  Bernd C Kieseier; Heinz Wiendl
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study.

Authors:  Masoud Etemadifar; Mojtaba Kazemi; Ahmad Chitsaz; Ali Hekmatnia; Nazila Tayari; Amirhossein Ghazavi; Amir Hadi Maghzi
Journal:  J Res Med Sci       Date:  2011-01       Impact factor: 1.852

10.  Time dependent neuroprotection of mycophenolate mofetil: effects on temporal dynamics in glial proliferation, apoptosis, and scar formation.

Authors:  Fahim Ebrahimi; Marco Koch; Philipp Pieroh; Chalid Ghadban; Constance Hobusch; Ingo Bechmann; Faramarz Dehghani
Journal:  J Neuroinflammation       Date:  2012-05-08       Impact factor: 8.322
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.